Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02152761 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
A Phase 2 study of Muscle Wasting (Atrophy) After Hip Fracture Surgery, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 251
- Enrollment target
- 20
- Study locations
NCT02152761: Completed Phase 2 study of Muscle Wasting (Atrophy) After Hip Fracture Surgery, sponsored by Novartis Pharmaceuticals.
NCT02152761 is a Phase 2 study of Muscle Wasting (Atrophy) After Hip Fracture Surgery that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 251 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02152761, a Phase 2 study of Muscle Wasting (Atrophy) After Hip Fracture Surgery, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 251 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to assess if bimagrumab is safe and effective in patients with muscle wasting (atrophy) after hip fracture surgery.
Primary Outcome
Mixed Model for Repeated Measures (MMRM) of change from baseline in total LBM (kg) by treatment and visit To assess dose-response relationship of bimagrumab and facilitate an adequate dose selection for future phase III studies, without the need for supportive data from another dose-response finding study, at least three doses were required, ranging from a non-effective or minimally effective dose to a dose where maximal efficacy is expected. Original study was initiated with only two doses of b
Conditions Studied
Interventions
- OTHER placebo
- DRUG bimagrumab
Study Locations (20)
Other
- Novartis Investigative Site - Ciudad Autonoma de Bs As
- Novartis Investigative Site - Graz
- Novartis Investigative Site - Bruges
- Novartis Investigative Site - Genk
- Novartis Investigative Site - Ghent
- Novartis Investigative Site - Santiago
- Novartis Investigative Site - Barranquilla
Czech Republic
- Novartis Investigative Site - Brno
- Novartis Investigative Site - Hradec Králové
- Novartis Investigative Site - Pardubice
- Novartis Investigative Site - Pilsen
- Novartis Investigative Site - Prague
Arizona
- Novartis Investigative Site - Phoenix
California
- Novartis Investigative Site - El Cajon
Colorado
- Novartis Investigative Site - Denver
Georgia
- Novartis Investigative Site - Gainesville
Minnesota
- Novartis Investigative Site - Rochester
New York
- Novartis Investigative Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2014-09-16 |
| Est. Completion | 2018-10-25 |
| Phase | Phase 2 |
What the finished NCT02152761 record still lists
NCT02152761 is an interventional study that assigns participants to a tested intervention. The registered 251 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% higher).
The record links to 1 condition, with Muscle Wasting (Atrophy) After Hip Fracture Surgery appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT02152761 names 20 study sites across 10 states, led by Other, Czech Republic, Arizona.
Frequently Asked Questions
What is clinical trial NCT02152761 about?
NCT02152761 is a clinical study titled "Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery". The purpose of this study was to assess if bimagrumab is safe and effective in patients with muscle wasting (atrophy) after hip fracture surgery.
What is the current status of trial NCT02152761?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 251 participants. The study started on 2014-09-16. Estimated completion is 2018-10-25.
What conditions does trial NCT02152761 study?
This clinical trial studies the following conditions: Muscle Wasting (Atrophy) After Hip Fracture Surgery.
What interventions are being tested in trial NCT02152761?
The interventions under investigation include: placebo (OTHER), bimagrumab (DRUG).
Who is sponsoring clinical trial NCT02152761?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02152761 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Georgia, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02152761's enrollment target sits among peer trials
251 222nd of 2000 higher than 1,779 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06043817 · 251 participants · Phase 1
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
- NCT02314988 · 252 participants · Phase 2
Tranexamic Acid to Reduce Blood Loss in Spine Surgery
- NCT03941756 · 252 participants · NA
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- NCT05219617 · 252 participants · Phase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI